Literature DB >> 34099711

Proline/arginine dipeptide repeat polymers derail protein folding in amyotrophic lateral sclerosis.

Maria Babu1, Filippo Favretto1, Alain Ibáñez de Opakua1, Marija Rankovic2, Stefan Becker3, Markus Zweckstetter4,5.   

Abstract

Amyotrophic lateral sclerosis and frontotemporal dementia are two neurodegenerative diseases with overlapping clinical features and the pathological hallmark of cytoplasmic deposits of misfolded proteins. The most frequent cause of familial forms of these diseases is a hexanucleotide repeat expansion in the non-coding region of the C9ORF72 gene that is translated into dipeptide repeat polymers. Here we show that proline/arginine repeat polymers derail protein folding by sequestering molecular chaperones. We demonstrate that proline/arginine repeat polymers inhibit the folding catalyst activity of PPIA, an abundant molecular chaperone and prolyl isomerase in the brain that is altered in amyotrophic lateral sclerosis. NMR spectroscopy reveals that proline/arginine repeat polymers bind to the active site of PPIA. X-ray crystallography determines the atomic structure of a proline/arginine repeat polymer in complex with the prolyl isomerase and defines the molecular basis for the specificity of disease-associated proline/arginine polymer interactions. The combined data establish a toxic mechanism that is specific for proline/arginine dipeptide repeat polymers and leads to derailed protein homeostasis in C9orf72-associated neurodegenerative diseases.

Entities:  

Year:  2021        PMID: 34099711     DOI: 10.1038/s41467-021-23691-y

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  42 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

2.  Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS.

Authors:  Peter E A Ash; Kevin F Bieniek; Tania F Gendron; Thomas Caulfield; Wen-Lang Lin; Mariely Dejesus-Hernandez; Marka M van Blitterswijk; Karen Jansen-West; Joseph W Paul; Rosa Rademakers; Kevin B Boylan; Dennis W Dickson; Leonard Petrucelli
Journal:  Neuron       Date:  2013-02-12       Impact factor: 17.173

3.  Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers.

Authors:  Yi Lin; Eiichiro Mori; Masato Kato; Siheng Xiang; Leeju Wu; Ilmin Kwon; Steven L McKnight
Journal:  Cell       Date:  2016-10-20       Impact factor: 41.582

Review 4.  Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria.

Authors:  Michael J Strong; Sharon Abrahams; Laura H Goldstein; Susan Woolley; Paula Mclaughlin; Julie Snowden; Eneida Mioshi; Angie Roberts-South; Michael Benatar; Tibor HortobáGyi; Jeffrey Rosenfeld; Vincenzo Silani; Paul G Ince; Martin R Turner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-01-05       Impact factor: 4.092

5.  The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS.

Authors:  Kohji Mori; Shih-Ming Weng; Thomas Arzberger; Stephanie May; Kristin Rentzsch; Elisabeth Kremmer; Bettina Schmid; Hans A Kretzschmar; Marc Cruts; Christine Van Broeckhoven; Christian Haass; Dieter Edbauer
Journal:  Science       Date:  2013-02-07       Impact factor: 47.728

6.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 7.  C9orf72-mediated ALS and FTD: multiple pathways to disease.

Authors:  Rubika Balendra; Adrian M Isaacs
Journal:  Nat Rev Neurol       Date:  2018-09       Impact factor: 42.937

8.  C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles.

Authors:  Kyung-Ha Lee; Peipei Zhang; Hong Joo Kim; Diana M Mitrea; Mohona Sarkar; Brian D Freibaum; Jaclyn Cika; Maura Coughlin; James Messing; Amandine Molliex; Brian A Maxwell; Nam Chul Kim; Jamshid Temirov; Jennifer Moore; Regina-Maria Kolaitis; Timothy I Shaw; Bing Bai; Junmin Peng; Richard W Kriwacki; J Paul Taylor
Journal:  Cell       Date:  2016-10-20       Impact factor: 41.582

9.  Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72.

Authors:  Qiang Zhu; Jie Jiang; Tania F Gendron; Melissa McAlonis-Downes; Lulin Jiang; Amy Taylor; Sandra Diaz Garcia; Somasish Ghosh Dastidar; Maria J Rodriguez; Patrick King; Yongjie Zhang; Albert R La Spada; Huaxi Xu; Leonard Petrucelli; John Ravits; Sandrine Da Cruz; Clotilde Lagier-Tourenne; Don W Cleveland
Journal:  Nat Neurosci       Date:  2020-04-13       Impact factor: 24.884

10.  Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics.

Authors:  Steven Boeynaems; Elke Bogaert; Denes Kovacs; Albert Konijnenberg; Evy Timmerman; Alex Volkov; Mainak Guharoy; Mathias De Decker; Tom Jaspers; Veronica H Ryan; Abigail M Janke; Pieter Baatsen; Thomas Vercruysse; Regina-Maria Kolaitis; Dirk Daelemans; J Paul Taylor; Nancy Kedersha; Paul Anderson; Francis Impens; Frank Sobott; Joost Schymkowitz; Frederic Rousseau; Nicolas L Fawzi; Wim Robberecht; Philip Van Damme; Peter Tompa; Ludo Van Den Bosch
Journal:  Mol Cell       Date:  2017-03-16       Impact factor: 17.970

View more
  3 in total

Review 1.  CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics.

Authors:  Tirthankar Sen; Rajkumar P Thummer
Journal:  Neurotox Res       Date:  2022-08-31       Impact factor: 3.978

2.  Peptidyl Prolyl Isomerase A Modulates the Liquid-Liquid Phase Separation of Proline-Rich IDPs.

Authors:  Maria Babu; Filippo Favretto; Marija Rankovic; Markus Zweckstetter
Journal:  J Am Chem Soc       Date:  2022-08-26       Impact factor: 16.383

3.  C9-ALS-Associated Proline-Arginine Dipeptide Repeat Protein Induces Activation of NLRP3 Inflammasome of HMC3 Microglia Cells by Binding of Complement Component 1 Q Subcomponent-Binding Protein (C1QBP), and Syringin Prevents This Effect.

Authors:  Ru-Huei Fu; Chia-Wen Tsai; Shao-Chih Chiu; Shih-Ping Liu; Yu-Ting Chiang; Yun-Hua Kuo; Woei-Cherng Shyu; Shinn-Zong Lin
Journal:  Cells       Date:  2022-10-05       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.